Literature DB >> 1722471

Successful treatment of a case of hepatocellular carcinoma with tumor necrosis factor and local hyperthermia.

M Maeda1, N Watanabe, N Yamauchi, Y Tsuji, Y Niitsu.   

Abstract

A case of unresectable hepatocellular carcinoma which responded favorably to combined therapy with tumor necrosis factor (TNF) and local hyperthermia is reported. A 58-year-old man was admitted to our hospital in June 1988 for treatment of hepatocellular carcinoma affecting S4 and S8. After three sessions of transcatheter arterial embolization (TAE) therapy, the serum alpha 1-fetoprotein level decreased, and a reduction in the size of the lesions was also noted. Thereafter, the patient received local hyperthermia once a week (60 minutes of irradiation from a Thermotron-RF8 at 1,100W), but the alpha 1-fetoprotein level increased again in February 1989. On examination, enlargement of the S8 lesion and a new nodule in S7 were recognized. Since TAE was contraindicated due to liver dysfunction, human recombinant TNF (1 x 10(6)U) was given by intravenous infusion together with local hyperthermia once a week. Eight sessions of the combined therapy reduced the serum alpha 1-fetoprotein level markedly (7,512.0 to 2,782.0 pg/ml) and after eighteen sessions, 58.1% regression of tumor size (partial response) on computed tomography scans was observed. This anecdotal case supports previous experimental evidence suggesting that TNF plus hyperthermia may be effective for treating unresectable hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722471     DOI: 10.1007/bf02782867

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  8 in total

1.  Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis.

Authors:  Y Niitsu; N Watanabe; H Umeno; H Sone; H Neda; N Yamauchi; M Maeda; I Urushizaki
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

2.  Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia.

Authors:  N Watanabe; Y Niitsu; H Umeno; H Sone; H Neda; N Yamauchi; M Maeda; I Urushizaki
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

3.  Hepatic artery embolization in 120 patients with unresectable hepatoma.

Authors:  R Yamada; M Sato; M Kawabata; H Nakatsuka; K Nakamura; S Takashima
Journal:  Radiology       Date:  1983-08       Impact factor: 11.105

4.  Phase I study of recombinant human tumor necrosis factor.

Authors:  K Kimura; T Taguchi; I Urushizaki; R Ohno; O Abe; H Furue; T Hattori; H Ichihashi; K Inoguchi; H Majima
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Radiofrequency thermotherapy for malignant liver tumors.

Authors:  Y Nagata; M Hiraoka; K Akuta; M Abe; M Takahashi; S Jo; Y Nishimura; S Masunaga; M Fukuda; H Imura
Journal:  Cancer       Date:  1990-04-15       Impact factor: 6.860

6.  Radiofrequency capacitive hyperthermia for deep-seated tumors. II. Effects of thermoradiotherapy.

Authors:  M Hiraoka; S Jo; K Akuta; Y Nishimura; M Takahashi; M Abe
Journal:  Cancer       Date:  1987-07-01       Impact factor: 6.860

7.  Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.

Authors:  T Ishikawa; M Imawari; T Moriyama; S Ohnishi; N Matsuhashi; G Suzuki; F Takaku
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

8.  Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor.

Authors:  T Shirai; H Yamaguchi; H Ito; C W Todd; R B Wallace
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

  8 in total
  1 in total

1.  Enhancement of blood stasis and vascular permeability in Meth-A tumors by administration of hyperthermia in combination with tumor necrosis factor.

Authors:  H Umeno; N Watanabe; N Yamauchi; N Tsuji; T Okamoto; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1994-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.